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ABSTRACT 
The therapy was carried out by inhalation of medicinal plants to cure illness of respiratory tract by ancient people. A wide range of dry 
powder inhaler devices are presently available on the market to convey drugs into lungs with a view to capitalize on drug delivery with low 
variability. Drug powder inhalers also face copious clinical challenges, particularly related to capricious patient factors such as age, clinical 
condition and inspiratory flow. Due to the drug formulation and the design of devices, different drug powder inhalers do not demonstrate the 
same performance and manufacturers are taking an assortment of device design approaches. The characteristics of an ideal drug powder 
inhaler, current innovations in powder formulation and device design are not unanimously unswerving in terms of dose variability, clinical 
efficacy, user friendliness and economy. Particle Size of active pharmaceutical ingredient must be present in size range about 1-10 μm which 
also assurance that the patient gets the same dose every time at dissimilar airflow rate. Drug powder inhaler are formulated using four types 
of formulation strategies such as; Carrier free, Drug carrier, Drug additive, Drug carrier additive. Lung deposition study is accomplished by 
‘Twin Stage Impingner’. The interior breath gadget is vital in accomplishing adequate transference of breathed in medication to lung which 
fundamentally grouped in view of measurements sort into single-unit and multi-dosage stores.  
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INTRODUCTION: 
The dry powder inhaler device is paramount to the 
triumph of a DPI product. It is the medium the 
formulation is delivered through for local or systemic 
effect via pulmonary the route. The thriving delivery of 
drugs into the deep lung depends on the integration 
between device recital and powder formulations. The 
amalgamation of the device and the formulation needs 
to demonstrate safety, usefulness, bioequivalence and 
steadfastness for product approval. Numerous factors 
impinge on the device performance. Some of the factors 
include mouth piece configuration, grid structure and 
mouthpiece length, impaction angle of the powder with 
devices and air inlet size. Due to the complexity and 
various configurations of the device, there are numerous 
device designs. 
1, 2, 3
 
Development of pharmaceuticals for inhalation is 
fundamentally a challenging job as it involves 
formulation and selection of device for aerosol 
dispersion. The lungs have lower buffering capacity 
than any other delivery sites which limits the range of 
excipients that could augment the delivery outcomes. 
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Development of inhalation devices: 
Development of inhalation devices have diverged into 3 
distinct classes:   
 Nebulizers 
 Pressurized metered dose inhalers (pMDIs) 
 Dry powder inhalers (DPI) 
DRY POWDER INHALERS: 
DPIs are devices through which a drug powder 
formulation of an active drug is delivered for local and 
systemic effect via pulmonary route. In DPIs, the drug 
particles (<5μm) are blended with the suitable large 
carrier (e.g. Lactose), to improve the flow properties and 
dose uniformity and the dry powders are delivered to the 
lung through a device known as Dry Powder Inhalers. 
Powder deagglomeration and aeroionisation of the 
formulation occurs via patients own effort. In order to 
achieve this, a high turbulence is needed to break the 
large agglomerates to the smaller, fine and inhalable 
particles. 
4
 
Characteristics of ideal DPI systems: 
5
 
 Simple and comfortable to use 
 It should be compact and economical 
 Highly reproducible fine particle dosing 
 Reproducible emitted doses 
 Powder should be physically and chemically stable 
 Minimal extra-pulmonary loss of drying. - Low 
oropharyngeal deposition. - Low device retention. - 
Low exhaled loss 
 Multidose system 
 
 
Figure 1: Classification of dry powder inhaler 
 
Capsule Based Devices: 
6, 7
 
Capsule based devices generally have a chamber to store 
a capsule. The capsule is broken by external force by 
action of twist or pins. Powder is released from the 
capsule upon aspiration. 
Examples: Aerohaler, Aerolizer, Arcus, Axahaler, 
Braunform, Breezhaler, Cipla rotahaler, DOTT, Eclipse, 
Rohahaler.  
A simple capsule based device is the Rotahaler as shown 
in Figure 2. The device has a barrel-shaped cap and body 
shell. The cap has two holes, one for capsule insert and 
the other one is for air inlet during aspiration. The body 
serves as a mouthpiece to be inserted into mouth. There 
is a grid between the cap and the body. The grid has 
many functions, it generates small eddies and allows 
high speed collisions for the drug particles. The space 
between cap and grid is the capsule chamber. When in 
use, the patient inserts the capsule prefilled with the drug 
into the cap. The drug powder is released from the 
capsule into the device chamber by twisting the cap and 
body. Powder will fluidize when the patient breathes 
through the mouthpiece. Drug particles pass through the 
grid and eventually deposit in the lung following the air 
stream. 
 
Figure 2: Illustration of Rotahaler 
 
Figure 3: Illustration of Aerolizer 
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Another capsule based device is the Aerolizer (Figure 3). 
It has a capsule chamber in the base of the inhaler, ports 
for air inlet, pins near the air inlet, grid in between the 
capsule chamber and the mouthpiece. The powder is 
released by piercing the capsule by the pins. 
6,7
 
Blister Based Device: 
8, 9
 
Blister based devices normally have a ring of aluminum 
blisters inside the device. Each blister contains one dose 
of drug pre-dispensed. The device also has a dose 
counter as a dosing indication. Drug powder is released 
by piercing the blister before inhalation. The drug 
powder is carried away by the air stream created by the 
patient’s inhalation. Examples are: Acu breathe, Acu-
breathe single dose, Prohaler, Puffhaler, Multihaler, 
Gyrohaler, Forspiro, Elpenhaler, Diskhaler  
 
 
Figure 4: Illustration of microdose 
 
Reservoir/Cartridge Based Device:  
The reservoir/cartridge based device has a powder 
chamber to store medicament. The device has a 
mechanism to dispense the powder each time during 
inhalation. This Multiple use device has a dosing meter. 
Examples are: Clickhaler. C-Haler, Bespak unit dose, 
Aespironics DPI, Cricket, Duohaler, E-flex, Genuair, 
Novolizer, PADD, Pulvinal, Skyehaler, Miathaler, LRRI 
DPI. 
10 
 
 
Figure 5: Novolizer 
 
Fomrulation of DPI: 
Formulation classification of DPI: 
 API production 
 Formulation of API with or without carrier. 
 Integration of formulation into device. 
Inhaled drug combinations are generally considered a 
unique medication whose in vitro performance and in 
vivo efficacy must be demonstrated.  
1. A dose metering mechanism. 
2. An aerosolization mechanism. 
3. A deaggregation mechanism. 
4. An adaptor to direct the aerosol into patient mouth 
Table 1: Main ingredients used in formulation of 
drug powder inhalation: 
S.No Ingredients Purpose 
01. Drug Active pharmaceutical 
ingredient 
02. Iso propyl alcohol Solvent 
03. Lactose Carrier 
04. Purified water Solvent 
 
Integration of formulation in a DPI device: 
In the development of a new DPI formulation, DPI 
device is the primary facto of concern. It is essential to 
have knowledge about computational fluid dynamics 
while designing DPI devices. Particle flow, shear stress 
and potential particle impaction within the device is 
analysed by computational fluid dynamics. 
Consequently this data may be utilized to estimate the in 
vitro aeroionisation efficiency of an active 
pharmaceutical ingredient. 
11 
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Figure 6: Principles of design of DPI 
 
Factors affecting devices of drug powder inhaler: 
12
 
 Humidity 
 Physical property of powder 
 Drug carrier and carrier size 
 Particle engineering 
Characterization of drug powder inhaler: 
13
 
 Appearance and color 
 Sieve analysis 
 Particle size analysis 
 Moisture content 
 Laser diffraction 
 Flow properties of Powder: Carr’s Flowability 
Index: The flow properties of a DPI were measured 
by the Carr’s method which involves following four 
tests: 
1) Angle of repose 
2) Compressibility 
3) Angle of spatula 
4) Uniformity coefficient 
Analytical testing to finished product 
1) Identity 
2) Microbial limit test 
3) Water content 
4) Foreign particulate matter 
Respirable particles: 
14
 
The optimal particle size of respirable paticles are 1-5 
µm. Systemic particle size of less than 2 µm is needed 
for drug deposition. In oropharyngeal region, particles 
size greater than 5 µm deposits and improves systemic 
effects. The particle deposition in the lung depends upon 
aerodynamic particle nature such as particle size, 
particle density, particle shape, hygrocopicity and 
electric charge. 
Process validation for drug powder inhalation: 
15
 
There are three stages of process validation: 
 Process design or process pre qualification 
 Process qualification 
 Continued process qualification 
Protocol of process validation for drug powder 
inhaler: 
 Protocol approval sheet 
 Table of contents 
 Scope and objectives 
 Validation term and responsibility 
 Steps for validation and acceptance criteria 
 Process flow chart 
 Procedure 
 For review of raw material/packing material 
 Evaluation of active raw material 
 Evaluation of inactive raw material 
 Qualification of equipment 
 Test instrument qualification 
 Test instrument calibration 
 Revalidation criteria 
 Reference document 
 Product details  
 Raw material for bulk manufacturing and their 
function 
 Packing material detail 
 Equipment detail 
 Manufacturing process flow chart 
 Critical process parameters 
 In process specification 
 Sampling procedure and testing plan 
 Revalidation criterion 
 Change protocol 
 Stability 
 Deviations 
 Incidence 
 Conclusion 
 Report and approval 
Process validation master plan: 
A validation master plan is a document that summarizes 
the company’s philosophy, intenstions and approaches 
to be sued for establishing adequacy. It should provide 
an overview of the entire validation operation, its 
organizational structure, its content and planning. The 
main elements consists the list of items to be validated 
and planning schedule. 
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Dispensing packing and raw material 
 
Granulation (FBD) 
 
Micronization (Air jet mill) 
 
Sieving (Vibro sifter) 
 
Blending (Turbo blender) 
 
Empty capsule 
 
Filling 
 
Primary packing 
 
Secondary packing 
 
Dispatch 
General Flow diagram of manufacturing process of dry powder inhaler 
 
CONCLUSION: 
As drug powder inhaler have several benefits like 
propellant free nature, high patient compliance, high dose 
carrying capacity and drug stability it has become topic 
of interest for the dealing of diseases like: asthma, 
chronic obstructive pulmonary disease. It is estimated by 
WHO that worldwide, some 300 million people suffer 
from Asthma and 240 million people from chronic 
obstructive pulmonary disease. The potential research in 
drug powder inhaler will integrate drug in a matrix 
particle to attain precise pulmonary drug deposition and 
most likely to accomplish intracellular drug delivery 
particularly, proteins, peptides, plasmids, DNA etc. The 
aim of inhaler needs upgrading to meet requirements of 
an idyllic inhaler. An enhanced understanding of the 
influencing properties of powder on the performance of 
drug powder inhaler will assist to tackle the challenges in 
the growth of drug powder inhalation formulation and 
inhaler devices for most advantageous therapeutic 
benefits. 
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